Avidity Biosciences, Inc. IPO Research Information

Avidity Biosciences, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Avidity Biosciences, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Avidity Biosciences, Inc.	RNA - NASDAQ	$14.00-$16.00	$18.00	$26.50	14.4 million	6/12/2020
Underwriter(s): Cowen, SVB Leerink, Credit Suisse, Wells Fargo Securities
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2020-05-22 Terms Added 2020-06-08 Terms Changed 2020-06-11

Avidity Biosciences, Inc. Quote & Chart - Click for current quote - RNA

About Avidity Biosciences, Inc. (adapted from Avidity Biosciences, Inc. prospectus):
They are pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "RNA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.